Volume 26, Number 2—February 2020
Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand
|Genotypic-resistance profile||Frequency, %
||Community patients||SHC patients||All patients|
|Macrolide + fluoroquinolone||+||+||–||12.5||12.1||12.3|
|Macrolide + fluoroquinolone||+||+||+||2.1||15.1||7.4|
*SHC, sexual health clinic; +, positive; –, negative.
Page created: January 20, 2020
Page updated: January 20, 2020
Page reviewed: January 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.